Abstract
ThPOK is best known as a regulator of CD4+ T cell lineage commitment, although it was initially cloned as a suppressor of collagen expression in the skin. The role of ThPOK has not been formally established in humans since individuals with damaging variants in ThPOK have not yet been identified. Here, we report the first case of a human with a damaging heterozygous de novo variant in ThPOK causing a syndrome encompassing CD4+ T cell deficiency, allergy, fibroinflammatory interstitial lung disease, developmental delay, and growth failure. The patient’s variant, ThPOKK360N, exhibited abnormal multimorphic activity, including interfering with ThPOKWT in regulating gene regulation (antimorph). Protein-DNA interaction assays showed inability of ThPOKK360N to bind to wild-type consensus sequences (amorph) and revealed a novel DNA-binding specificity (neomorph). Single-cell RNA sequencing of peripheral blood revealed potential developmental defects in maturation and activation of CD4+ and CD8+ T cells (hypomorph). To establish causality, we recapitulated the observed cellular defects in lentivirally transduced healthy control T cells and pulmonary fibroblasts. Transcriptomic analysis showed that T cells transduced with ThPOKK360N lacked the upregulation of activation, proliferation, and functional pathways observed in ThPOKWT-transduced cells. When overexpressed in healthy control fibroblasts, ThPOKK360N significantly increased the expression of pro-fibrotic genes implicated in pulmonary fibrosis, indicating a defect in regulating collagen expression. This novel human disease caused by a multimorphic variant in ThPOK confirms its role in CD4+ T cell development in an intact human context, while also revealing an unanticipated role for ThPOK in T cell function and the regulation of fibrotic pathways in fibroblasts.
One sentence summary Discovery of a human with pathogenic multimorphic genetic change in ThPOK establishes ThPOK as essential for human T cell development and reveals its novel role as a regulator of fibrosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Canadian Institutes of Health Research PJQ-173584 (SET), Genome British Columbia SIP007 (SET), Tier 1 Canada Research Chair in Pediatric Precision Health (SET), Aubrey J. Tingle Professor of Pediatric Immunology (SET), Health Professional-Investigator of the Michael Smith Foundation for Health Research (CMB), Providence Healthcare Research Institute Early Career Investigator Award (CMB), Vanier Canada Graduate Scholarship (MV-S), Four-Year Doctoral Fellowship (MV-S, SS)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research study protocols were approved by the University of British Columbia Clinical Research Ethics Board (H15-00641).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
